Bridgebio Pharma, INC Form 4 insider transactions

BridgeBio Pharma's CEO, Neil Kumar, sold a total of 27,389 shares of common stock on November 19, 2024, under a pre-arranged 10b5-1 trading plan.

BridgeBio Pharma's CFO, Brian C. Stephenson, sold 4,156 shares of common stock at an average price of $22.4102, as part of a pre-arranged 10b5-1 trading plan.

BridgeBio Pharma's CEO, Neil Kumar, executed transactions involving common stock and restricted stock units, as detailed in a recent SEC filing.

BridgeBio Pharma's President and COO, Thomas Trimarchi, sold 17,936 shares of common stock to cover tax obligations related to vesting restricted stock units.

Brian Stephenson, CFO of BridgeBio Pharma, reported the acquisition of 25,799 shares and the disposal of 13,077 shares to cover tax obligations related to vesting restricted stock units.

KKR Genetic Disorder L.P. sold 5.8 million shares of BridgeBio Pharma at $25.75 per share on September 13, 2024.

CEO Neil Kumar of BridgeBio Pharma reports multiple transactions involving common stock and restricted stock units, including sales under a pre-arranged Rule 10b5-1 plan.

Brian Stephenson, CFO of BridgeBio Pharma, reports the acquisition and disposal of common stock and restricted stock units.

Thomas Trimarchi, President and COO of BridgeBio Pharma, disposed of 17,936 shares of common stock to satisfy tax obligations related to vesting restricted stock units.

Thomas Trimarchi, President and COO of BridgeBio Pharma, reports the acquisition of restricted stock units and stock options.

Hannah Valantine, a director of BridgeBio Pharma, acquired stock options for 26,014 shares on June 21, 2024.

Director Randal W. Scott acquired stock options for 26,014 shares of BridgeBio Pharma, Inc. on June 21, 2024.

Director Ali J. Satvat acquires stock options in BridgeBio Pharma, Inc.

James C. Momtazee, a director of BridgeBio Pharma, Inc., acquired stock options for 26,014 shares on June 21, 2024.

Director Fred Hassan acquired stock options for 26,014 shares of BridgeBio Pharma, Inc. on June 21, 2024.

Director Andrea Ellis acquired stock options for 26,014 shares of BridgeBio Pharma, Inc. on June 21, 2024.

Director Frank McCormick reports acquisition of shares and stock options in BridgeBio Pharma, Inc.

Director Andrew Lo acquired stock options for 26,014 shares of BridgeBio Pharma, Inc. on June 21, 2024.

Director Charles J. Homcy acquired stock options for 26,014 shares of BridgeBio Pharma, Inc. on June 21, 2024.

Director Ronald J. Daniels acquired stock options in BridgeBio Pharma, Inc. on June 21, 2024.

Douglas A. Dachille, a director of BridgeBio Pharma, acquired stock options for 26,014 shares on June 21, 2024.

Jennifer E. Cook, a director of BridgeBio Pharma, acquired stock options for 26,014 shares of common stock on June 21, 2024.

Eric Aguiar, a director of BridgeBio Pharma, acquired stock options for 26,014 shares of common stock on June 21, 2024.

Director Randal W. Scott sold BridgeBio Pharma shares on June 3rd and 4th, 2024, under a pre-arranged 10b5-1 trading plan.

CEO Neil Kumar reports the vesting and tax-related disposal of BridgeBio Pharma (BBIO) stock and restricted stock units.

Brian Stephenson, CFO of BridgeBio Pharma, reports the vesting and subsequent tax withholding of shares related to restricted stock units.

CEO Neil Kumar reports acquisition of stock options and restricted stock units in BridgeBio Pharma, Inc.

Brian Stephenson, CFO of BridgeBio Pharma, reports the acquisition of stock options and restricted stock units.

Director Randal W. Scott sold 2,500 shares of BridgeBio Pharma, Inc. common stock at $34 per share on March 1, 2024, under a pre-arranged 10b5-1 trading plan.